Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories rose 4.62% to $123.22 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,118.71 and the Dow Jones Industrial Average rising 0.
What’s Driving Abbott Laboratories (ABT) Stock’s 9.45% Surge Over the Past Month?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to
Why Is Abbott Laboratories (ABT) Stock Surpassing 6.96% from Its 50-Day SMA?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.
Abbott Laboratories' SWOT analysis: stock poised for growth amid challenges
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to InvestingPro data,
Abbott Laboratories Reports Strong 2024 Financial Results
Abbott Laboratories ( ($ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories presented to its
Barclays raises Abbott Labs stock price target to $158
Barclays (LON:BARC) analyst Matt Miksic increased the price target on Abbott Labs (NYSE:ABT) shares to $158 from $149, while reiterating an Overweight rating on the stock. The adjustment comes in ...
Abbott Labs' Ensure, made in Columbus, hits multibillion-dollar milestone
A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...
Barclays Remains a Buy on Abbott Laboratories (ABT)
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Top Stock Reports for Cisco, Abbott & Coca-Cola
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Abbott ...
Abbott sued over its marketing of potentially harmful toddler milk
Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Paul MacDonald's Past Picks: Stryker, Abbott Laboratories and Elevance Health
Paul MacDonald, CIO and portfolio manager at Harvest Portfolios Group Focus, shares his past picks; Stryker, Abbott ...